Viswanathan Anand, Rocca Walter A, Tzourio Christophe
Department of Neurology and Clinical Trials Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Neurology. 2009 Jan 27;72(4):368-74. doi: 10.1212/01.wnl.0000341271.90478.8e.
In recent years, accumulating evidence has suggested that vascular risk factors contribute to Alzheimer disease (AD). Vascular dementia had been traditionally considered secondary to stroke and vascular disease. It has been traditionally distinguished from AD, considered to be a purely neurodegenerative form of dementia. However, in light of this more recent literature, it appears that there is a spectrum: ranging from patients with pure vascular dementia to patients with pure AD and including a large majority of patients with contributions from both Alzheimer and vascular pathologies. In this article, we discuss the impact of vascular risk factors on AD and its consequences at the individual level and at the population level by highlighting the concept of attributable risk. We then discuss the key questions and next steps involved in designing a therapeutic trial to control vascular risk factors for the prevention of dementia.
近年来,越来越多的证据表明血管危险因素与阿尔茨海默病(AD)有关。血管性痴呆传统上被认为是中风和血管疾病的继发性疾病。它传统上与AD相区分,AD被认为是一种纯粹的神经退行性痴呆形式。然而,根据最近的这些文献,似乎存在一个谱系:从纯血管性痴呆患者到纯AD患者,还包括绝大多数同时存在阿尔茨海默病和血管病变的患者。在本文中,我们通过强调归因风险的概念,讨论血管危险因素对AD的影响及其在个体层面和人群层面的后果。然后,我们讨论设计一项治疗试验以控制血管危险因素来预防痴呆所涉及的关键问题和后续步骤。